{"hands_on_practices": [{"introduction": "This practice applies the Hardy-Weinberg principle, a cornerstone of population genetics, to a common scenario in medical genetics. By using the observed prevalence of a rare autosomal recessive disorder like Epidermolysis Bullosa, you will calculate the underlying frequency of heterozygous carriers in the population, a crucial metric for genetic counseling and public health screening strategies. [@problem_id:4442430]", "problem": "A single-pathogenic-allele model is often used to approximate the genetic load of a rare autosomal recessive skin disorder. Consider the case of Epidermolysis Bullosa (EB), a mechanobullous disease with several subtypes, some of which are inherited as autosomal recessive traits. Assume a single autosomal recessive EB-causing allele in a large, randomly mating population with no mutation, migration, or selection, and complete penetrance of the recessive genotype. Let the mutant allele frequency be $q$ and the wild-type allele frequency be $p$, with $p+q=1$. Define the carrier frequency as the proportion of heterozygotes, and assume the observed disease prevalence equals the frequency of homozygous recessives. In an epidemiologic study, the population prevalence of this autosomal recessive EB subtype is reported as $q^{2} = \\frac{1}{100{,}000}$. Using only the assumptions stated and fundamental population genetics principles, derive the expected carrier frequency from first principles and then compute its numerical value. Express your final answer as a decimal fraction and round to four significant figures.", "solution": "The problem statement will first be validated against the required criteria.\n\n### Step 1: Extract Givens\n-   **Model**: Single-pathogenic-allele model for a rare autosomal recessive skin disorder.\n-   **Disorder**: Epidermolysis Bullosa (EB), autosomal recessive subtype.\n-   **Population Assumptions**: Large, randomly mating, no mutation, no migration, no selection.\n-   **Genetic Parameters**:\n    -   Mutant allele frequency: $q$\n    -   Wild-type allele frequency: $p$\n    -   Allele frequency relation: $p+q=1$\n-   **Phenotype-Genotype Correlation**:\n    -   Complete penetrance of the recessive genotype.\n    -   Observed disease prevalence equals the frequency of homozygous recessives.\n-   **Definitions**:\n    -   Carrier frequency is the proportion of heterozygotes.\n-   **Data**:\n    -   Population prevalence (frequency of homozygous recessives): $q^2 = \\frac{1}{100,000}$.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientifically Grounded**: The problem is grounded in the fundamental principles of population genetics, specifically the Hardy-Weinberg equilibrium (HWE). The assumptions provided (large, randomly mating population with no mutation, migration, or selection) are the explicit conditions for HWE. The application to a rare autosomal recessive disease like an EB subtype is a standard and scientifically valid use-case for this model.\n-   **Well-Posed**: The problem is well-posed. It provides all necessary data ($q^2$) and a clear theoretical framework (HWE) to calculate a uniquely defined quantity (the carrier frequency, $2pq$).\n-   **Objective**: The problem is stated using precise, objective, and quantitative language.\n\n### Step 3: Verdict and Action\nThe problem is scientifically sound, well-posed, and objective. It contains no invalidating flaws. Therefore, it is deemed **valid**, and a solution will be provided.\n\n### Solution Derivation\nThe problem asks for the expected carrier frequency of a rare autosomal recessive disorder in a population under specific assumptions. The assumptions stated—a large, randomly mating population with no mutation, migration, or selection—are the conditions for the Hardy-Weinberg equilibrium (HWE).\n\nAccording to the principles of HWE, if we consider a single gene locus with two alleles, a wild-type allele with frequency $p$ and a mutant allele with frequency $q$, the allele frequencies in the population remain constant from generation to generation. The relationship between these allele frequencies is given by:\n$$p + q = 1$$\n\nThe genotype frequencies in the population can be predicted from the allele frequencies. For an autosomal locus, the genotype frequencies at equilibrium are given by the terms of the binomial expansion of $(p+q)^2$:\n-   Frequency of homozygous wild-type individuals: $p^2$\n-   Frequency of heterozygous individuals (carriers): $2pq$\n-   Frequency of homozygous recessive individuals (affected, given complete penetrance): $q^2$\n\nThe sum of these genotype frequencies must equal $1$:\n$$p^2 + 2pq + q^2 = (p+q)^2 = 1^2 = 1$$\n\nThe problem states that the prevalence of this autosomal recessive EB subtype is $\\frac{1}{100,000}$. It also specifies that this prevalence equals the frequency of homozygous recessives. Therefore, we have:\n$$q^2 = \\frac{1}{100,000} = 10^{-5}$$\n\nFrom this, we can calculate the frequency of the mutant allele, $q$:\n$$q = \\sqrt{q^2} = \\sqrt{10^{-5}}$$\n\nOur goal is to find the carrier frequency, which is defined as the proportion of heterozygotes, $2pq$. First, we must find the frequency of the wild-type allele, $p$:\n$$p = 1 - q = 1 - \\sqrt{10^{-5}}$$\n\nNow, we can substitute the expressions for $p$ and $q$ into the formula for the carrier frequency:\n$$\\text{Carrier Frequency} = 2pq = 2 \\left(1 - \\sqrt{10^{-5}}\\right) \\sqrt{10^{-5}}$$\nThis expression can be simplified as:\n$$\\text{Carrier Frequency} = 2\\sqrt{10^{-5}} - 2\\left(\\sqrt{10^{-5}}\\right)^2 = 2\\sqrt{10^{-5}} - 2(10^{-5})$$\n\nTo obtain the numerical value, we first compute $q$:\n$$q = \\sqrt{10^{-5}} = \\sqrt{0.00001} \\approx 0.00316227766$$\nThen, we compute $p$:\n$$p = 1 - q \\approx 1 - 0.00316227766 = 0.99683772234$$\nNow we compute the carrier frequency, $2pq$:\n$$\\text{Carrier Frequency} = 2pq \\approx 2 \\times (0.99683772234) \\times (0.00316227766)$$\n$$\\text{Carrier Frequency} \\approx 0.00630459428$$\nThe problem requires the final answer to be rounded to four significant figures. The first significant digit is the $6$ in the thousandths place. The first four significant digits are $6$, $3$, $0$, and $4$. The fifth significant digit is $5$, which means we round the fourth digit ($4$) up to $5$.\n\nThus, the rounded numerical value for the carrier frequency is $0.006305$.\nIt is worth noting that for a rare allele where $q \\ll 1$, the carrier frequency $2pq = 2(1-q)q$ is often approximated as $2q$. In this case, $2q \\approx 2 \\times 0.00316227766 \\approx 0.00632455$, which rounds to $0.006325$. While close, this approximation ignores the term $-2q^2$, and the problem's request for a derivation from first principles implies the use of the full, exact expression $2pq$. The calculated value $0.006305$ is derived from the exact formula.", "answer": "$$\\boxed{0.006305}$$", "id": "4442430"}, {"introduction": "Moving from population-level data to molecular mechanisms, this exercise challenges you to predict a clinical outcome from a specific genetic finding. You will analyze how an in-frame exon skipping event in the $\\mathrm{COL7A1}$ gene impacts the critical Gly-X-Y structure of type VII collagen, allowing you to infer the resulting disease severity in dystrophic EB. This practice hones the essential skill of genotype-phenotype correlation based on first principles of molecular and protein biology. [@problem_id:4442436]", "problem": "A researcher is evaluating a splice-site variant in the collagen type VII alpha 1 chain gene ($\\mathrm{COL7A1}$), which encodes the $\\alpha$ chain of type VII collagen that forms anchoring fibrils in the dermal-epidermal junction. Epidermolysis bullosa (EB) is classified mechanistically by the level of skin cleavage and genetically by the affected structural protein. Dystrophic EB involves defective type VII collagen, and the severity reflects whether the variant causes complete loss of function or exerts a dominant-negative effect on the collagen triple helix. The candidate variant is a canonical splice donor mutation adjacent to an exon within the triple-helical domain of $\\mathrm{COL7A1}$. Complementary DNA analysis demonstrates complete skipping of the exon, with an exon length of $117$ nucleotides. The messenger ribonucleic acid (mRNA) shows preserved reading frame and no evidence of nonsense-mediated decay. The deleted peptide segment lies within the uninterrupted Gly-X-Y repeat region of the triple helix. No other pathogenic variants are present in the gene. Using the Central Dogma of molecular biology (deoxyribonucleic acid to mRNA to protein) and the biophysical constraint that collagen triple helices require glycine at every third residue to pack the three chains, reason from first principles about how the number of residues removed by this exon skipping would impact the triple-helix register and the resulting assembly of type VII collagen anchoring fibrils. Then infer the most likely clinical severity category of EB in a homozygous individual for this splice-site variant.\n\nWhich of the following is the most accurate prediction?\n\nA. The in-frame skipping of a $117$-nucleotide exon ($39$ amino acids) in the triple-helical domain preserves the Gly-X-Y register, yields a shortened but partially functional type VII collagen, and is most consistent with recessive dystrophic epidermolysis bullosa of intermediate severity rather than severe generalized disease.\n\nB. The in-frame skipping shifts the Gly-X-Y periodicity and produces a dominant-negative effect on type VII collagen, most consistent with dominant dystrophic epidermolysis bullosa with severe generalized blistering.\n\nC. The skipped exon is within the noncollagenous $1$ (NC1) domain, abolishes binding to laminin $332$, and causes complete loss of anchoring fibrils with a lethal phenotype.\n\nD. Because the reading frame is preserved, there is minimal biological impact and individuals are asymptomatic due to redundancy in basement membrane proteins.", "solution": "The user has provided a problem in molecular genetics and dermatology to be validated and solved.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n-   **Gene:** Collagen type VII alpha 1 chain gene ($\\mathrm{COL7A1}$)\n-   **Protein Product:** $\\alpha$ chain of type VII collagen\n-   **Protein Function:** Forms anchoring fibrils in the dermal-epidermal junction.\n-   **Associated Disease:** Epidermolysis bullosa (EB); specifically, dystrophic EB (DEB) involves defective type VII collagen.\n-   **Disease Severity Mechanisms:** Severity reflects either (1) complete loss of function or (2) a dominant-negative effect on the collagen triple helix.\n-   **Genetic Variant:** A canonical splice donor mutation adjacent to an exon.\n-   **Variant Location:** Within the triple-helical domain of $\\mathrm{COL7A1}$.\n-   **mRNA Effect:** Complementary DNA (cDNA) analysis shows complete skipping of the adjacent exon.\n-   **Skipped Exon Size:** The length of the skipped exon is $117$ nucleotides.\n-   **mRNA Status:** The reading frame is preserved, and there is no evidence of nonsense-mediated decay (NMD).\n-   **Protein Domain Context:** The deleted peptide segment is within the uninterrupted Gly-X-Y repeat region of the triple helix.\n-   **Genetic State:** The individual is homozygous for this variant, and no other pathogenic variants are present in the gene.\n-   **Required Principles:** Central Dogma of molecular biology and the biophysical constraint that collagen triple helices require glycine (Gly) at every third residue.\n-   **Question:** Analyze the impact of the residue removal on the triple-helix register and protein assembly, and infer the most likely clinical severity category of EB in a homozygous individual.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding:** The problem is scientifically grounded. $\\mathrm{COL7A1}$, type VII collagen, dystrophic epidermolysis bullosa, splice-site mutations, exon skipping, the Gly-X-Y structure of collagen, and the concepts of dominant-negative vs. loss-of-function are all established principles in molecular biology, genetics, and dermatology.\n-   **Well-Posedness:** The problem is well-posed. It provides sufficient information (exon size, reading frame preservation, protein domain, homozygous state) to deduce the molecular consequences and infer a clinical phenotype based on established genotype-phenotype correlations in DEB.\n-   **Objectivity:** The problem statement is objective and uses precise, technical language.\n-   **Completeness/Consistency:** The information is internally consistent. A $117$-nucleotide deletion is a multiple of $3$, which is consistent with the statement that the reading frame is preserved and NMD is avoided. All necessary information to solve the problem is provided.\n-   **Realism/Feasibility:** The scenario is realistic. Splice-site mutations leading to in-frame exon skipping are a known disease mechanism. The relationship between the number of deleted amino acids and the preservation of the collagen structural motif is a classic concept in collagenopathies.\n-   **Structure and Clarity:** The problem is well-structured and uses clear, unambiguous terms.\n\n**Step 3: Verdict and Action**\nThe problem statement is **valid**. It is a well-formed question based on sound scientific principles. The solution process can proceed.\n\n### Solution Derivation\n\nThe problem requires a step-by-step analysis from the genetic mutation to the clinical phenotype, based on fundamental principles.\n\n1.  **From mRNA to Protein (Translation):**\n    The problem states that an exon of length $117$ nucleotides is skipped from the mature mRNA. The genetic code is a triplet code, where $3$ nucleotides encode $1$ amino acid. Therefore, the number of amino acids removed from the final protein is:\n    $$ \\text{Number of amino acids} = \\frac{\\text{Number of nucleotides}}{3} = \\frac{117}{3} = 39 $$\n    The problem states the reading frame is preserved, which is consistent with the deletion of a number of nucleotides that is an integer multiple of $3$. This deletion results in a protein that is shorter by $39$ amino acids but otherwise has the correct amino acid sequence downstream of the deletion.\n\n2.  **Impact on Protein Structure (Collagen Triple Helix):**\n    Type VII collagen, like other collagens, has a large triple-helical domain characterized by a repeating Gly-X-Y amino acid sequence. The formation of the stable triple helix requires glycine, the smallest amino acid, to be present at every third position to fit into the sterically hindered core of the helix.\n    The deletion removes $39$ amino acids from this domain. We must determine if this deletion disrupts the Gly-X-Y register. The length of the repeating unit is $3$ amino acids. The number of deleted amino acids is $39$. Since $39$ is an integer multiple of $3$ ($39 = 13 \\times 3$), the deletion removes exactly $13$ complete Gly-X-Y triplets.\n    This means that the amino acid sequence before the deletion ends with a Y-position residue, and the sequence immediately after the deletion begins with a Gly-position residue. The crucial Gly-X-Y periodicity is therefore **preserved** across the deletion junction. The resulting $\\alpha$ chain can align with other chains and form a triple helix.\n\n3.  **Impact on Protein Function and Assembly:**\n    Because the Gly-X-Y register is preserved, the shortened $\\alpha$ chains can likely trimerize and fold into a triple-helical molecule. However, this molecule will be shorter than its wild-type counterpart. This shortening will likely impair its ability to assemble into fully functional, stable anchoring fibrils at the dermal-epidermal junction. The protein is therefore not non-functional (null), but rather has reduced or partial function. Such an allele is termed hypomorphic.\n\n4.  **Inferring Clinical Phenotype (Homozygous State):**\n    The individual is homozygous for this variant. This means both $\\mathrm{COL7A1}$ alleles produce the same shortened, partially functional protein. No wild-type protein is produced.\n    -   **Dominant-Negative Effect:** A dominant-negative effect is ruled out. This mechanism typically occurs in heterozygotes, where a mutant protein interferes with the function of the wild-type protein produced from the normal allele (e.g., by incorporating into a trimer and disrupting its structure or function). Since the individual is homozygous, there are no wild-type chains for the mutant protein to \"poison\".\n    -   **Recessive Inheritance:** The disease results from the absence of fully functional protein, which is a recessive mechanism. The clinical phenotype depends on the residual function of the protein.\n    -   **Severity:** Complete loss of type VII collagen function (e.g., in individuals homozygous for null mutations) leads to the most severe form of the disease, known as severe generalized recessive dystrophic EB (RDEB-sev gen), characterized by extensive blistering, scarring, and high morbidity. Since the analysis here predicts the formation of a partially functional protein, one would expect a phenotype that is less severe than RDEB-sev gen. This corresponds to an intermediate or milder form of recessive dystrophic EB.\n\n**Conclusion:** The skipping of a $117$ nucleotide exon results in a $39$ amino acid in-frame deletion. As $39$ is a multiple of $3$, the Gly-X-Y register of the collagen triple helix is maintained. This allows for the production of a shortened but partially functional type VII collagen. In a homozygous individual, this leads to a recessive form of dystrophic EB with a phenotype of intermediate severity, which is less severe than the complete loss-of-function phenotype.\n\n### Option-by-Option Analysis\n\n**A. The in-frame skipping of a $117$-nucleotide exon ($39$ amino acids) in the triple-helical domain preserves the Gly-X-Y register, yields a shortened but partially functional type VII collagen, and is most consistent with recessive dystrophic epidermolysis bullosa of intermediate severity rather than severe generalized disease.**\n-   This statement correctly calculates the number of deleted amino acids ($39$).\n-   It correctly deduces that the Gly-X-Y register is preserved because $39$ is a multiple of $3$.\n-   It correctly infers that this leads to a shortened, partially functional protein.\n-   It correctly correlates this molecular finding in a homozygous individual with a recessive, intermediate-severity phenotype, which is less severe than the phenotype associated with complete loss of function.\n-   **Verdict: Correct.**\n\n**B. The in-frame skipping shifts the Gly-X-Y periodicity and produces a dominant-negative effect on type VII collagen, most consistent with dominant dystrophic epidermolysis bullosa with severe generalized blistering.**\n-   This statement incorrectly claims the Gly-X-Y periodicity is shifted. A deletion of $39$ ($=13 \\times 3$) amino acids preserves the register.\n-   It incorrectly proposes a dominant-negative effect. The individual is homozygous, making a dominant-negative mechanism inapplicable in its classic sense.\n-   It incorrectly concludes a dominant form of DEB. The genetic context (homozygosity for a hypomorphic allele) defines a recessive inheritance pattern.\n-   **Verdict: Incorrect.**\n\n**C. The skipped exon is within the noncollagenous $1$ (NC1) domain, abolishes binding to laminin $332$, and causes complete loss of anchoring fibrils with a lethal phenotype.**\n-   This statement incorrectly locates the deletion. The problem explicitly states the variant affects an exon \"within the triple-helical domain,\" not the NC1 domain.\n-   The functional consequence described (abolished binding to laminin $332$) is associated with the NC1 domain, not the triple-helical domain.\n-   The prediction of complete loss of function is less likely than partial function, as derived above.\n-   **Verdict: Incorrect.**\n\n**D. Because the reading frame is preserved, there is minimal biological impact and individuals are asymptomatic due to redundancy in basement membrane proteins.**\n-   This statement grossly underestimates the impact of deleting $39$ residues from the critical structural domain of type VII collagen. While preserving the reading frame is better than a frameshift, a significant deletion in a structural protein is not a 'minimal' impact.\n-   The claim of no symptoms is incorrect; defects in $\\mathrm{COL7A1}$ are known to cause severe skin disease.\n-   The role of type VII collagen in forming anchoring fibrils is unique and essential for robust epidermal adhesion; there is no simple redundancy that would fully compensate for its deficiency.\n-   **Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "4442436"}, {"introduction": "A definitive molecular diagnosis for autosomal recessive conditions often requires more than just identifying variants; it requires determining their phase. This problem tackles the critical distinction between variants located *in cis* (on the same allele) versus *in trans* (on opposite alleles), which determines whether an individual is a carrier or affected with compound heterozygosity. You will evaluate various molecular and bioinformatic methods for establishing phase, a fundamental step in modern genomic diagnostics. [@problem_id:4442428]", "problem": "A patient presents with neonatal-onset generalized blistering, mitten deformities, and scarring consistent with recessive dystrophic Epidermolysis Bullosa (EB). Epidermolysis Bullosa (EB) comprises inherited skin fragility disorders in which gene defects impair dermal-epidermal adhesion. Recessive dystrophic EB typically results from biallelic loss-of-function variants in the gene coding for type VII collagen. Whole Exome Sequencing (WES) of the proband identifies two heterozygous pathogenic variants in the same gene: a nonsense variant $v_1$ in exon $X$ and a canonical splice-site variant $v_2$ in exon $X+1$, separated by $d=200$ base pairs. The WES library uses paired-end reads of length $L=150$ base pairs, with a mean insert size $I=350$ base pairs and mean on-target depth $D=80\\times$. No copy-number variation is detected at the locus. Family history is noncontributory.\n\nFrom first principles of Mendelian inheritance, an autosomal locus has two alleles per individual, and autosomal recessive disease requires that both alleles harbor loss-of-function variants that abolish normal gene function. Distinguishing whether two heterozygous variants are on the same allele (in cis) or on opposite alleles (in trans) is essential to infer pathogenicity in an autosomal recessive disorder: in cis variants imply only one defective allele, whereas in trans compound heterozygosity implies both alleles are defective.\n\nSelect all options that present decisive evidence for the phase (in cis versus in trans) and robust methods to establish phase in this scenario. Consider the physical constraints of the library ($L$, $I$, $d$, $D$) and the biological definition of autosomal recessive inheritance. Assume standard capture performance and that $v_1$ and $v_2$ are rare and not present in population haplotype panels.\n\nA. Parental genotyping shows the mother is heterozygous for $v_1$ and wild type at $v_2$, the father is heterozygous for $v_2$ and wild type at $v_1$, and the proband carries both $v_1$ and $v_2$ in heterozygous state; this establishes in trans compound heterozygosity.\n\nB. Read-backed phasing in the proband identifies multiple paired-end fragments whose template molecules span both positions (distance $d$ within insert $I$), and in those molecules both $v_1$ and $v_2$ co-occur on the same molecule; this establishes an in cis configuration.\n\nC. Reverse Transcription Polymerase Chain Reaction (RT-PCR) followed by cloning of Complementary DNA (cDNA) amplicons spanning both sites from proband fibroblasts, with Sanger sequencing of individual clones, shows transcripts carrying either $v_1$ alone or $v_2$ alone but never both $v_1$ and $v_2$ on the same cDNA molecule; this supports an in trans configuration.\n\nD. Statistical phasing using population reference panels assigns $v_1$ and $v_2$ to different haplotypes with posterior probability $>0.95$; in the absence of parental data or read-backed phasing, this is sufficient to conclude in trans.\n\nE. Immunofluorescence microscopy demonstrating severely reduced type VII collagen at the dermal-epidermal junction in the proband establishes that $v_1$ and $v_2$ are in trans.\n\nF. Oxford Nanopore Technologies (ONT) long-read sequencing of a long-range Polymerase Chain Reaction (PCR) amplicon spanning both variants in the proband yields single-molecule reads where some reads carry $v_1$ with wild-type at $v_2$ and other reads carry $v_2$ with wild-type at $v_1$, with no reads carrying both variants simultaneously; this is decisive evidence for an in trans configuration.\n\nSelect all that apply.", "solution": "The problem requires an evaluation of methods to determine the phase of two heterozygous pathogenic variants, $v_1$ (a nonsense variant in exon $X$) and $v_2$ (a splice-site variant in exon $X+1$), in the context of recessive dystrophic Epidermolysis Bullosa (EB). For an autosomal recessive disease, the patient must have two non-functional alleles. If the two variants are on the same allele (in cis), the genotype is $(v_1, v_2)/(WT, WT)$, leaving one wild-type allele, which is inconsistent with a severe recessive phenotype. If the variants are on opposite alleles (in trans), the genotype is $(v_1, WT)/(WT, v_2)$, resulting in two non-functional alleles (compound heterozygosity), which explains the disease. Therefore, establishing the phase is critical for a definitive molecular diagnosis. We will evaluate each proposed method based on its ability to provide decisive evidence for the phase.\n\nA. This option describes parental genotyping. The principle of Mendelian inheritance states that a child inherits one allele from each parent. If the mother is heterozygous for $v_1$ (genotype $v_1/WT$) and wild-type for $v_2$ (genotype $WT/WT$), she can only transmit an allele containing $v_1$ or an allele containing $WT$. Her relevant haplotype is $v_1-WT$. Similarly, if the father is heterozygous for $v_2$ (genotype $v_2/WT$) and wild-type for $v_1$ (genotype $WT/WT$), his relevant haplotype is $WT-v_2$. For the proband to inherit both $v_1$ and $v_2$, they must have inherited the $v_1-WT$ allele from the mother and the $WT-v_2$ allele from the father. This unambiguously places the variants on opposite chromosomes in the proband. This is the gold standard for phasing and provides decisive evidence for an in trans configuration.\n**Verdict: Correct.**\n\nB. This option describes read-backed phasing using Whole Exome Sequencing (WES) data. This method relies on sequencing reads that physically span both variant locations. The problem states the read length is $L=150$ base pairs (bp), the mean insert size is $I=350$ bp, and the distance between variants is $d=200$ bp. Since $d > L$, a single read cannot cover both variants. However, a paired-end read strategy sequences the two ends of a longer DNA fragment (the insert). A read pair can provide phasing information if one variant is captured by the first read and the second variant is captured by the mate read. Let a DNA fragment start at genomic position $G$. The first read covers $[G, G+L-1]$ and the second read covers $[G+I-L, G+I-1]$. We need to find if there are fragment start positions $G$ such that one variant, $v_1$ at position $P_1$, falls in the first read, and the other, $v_2$ at position $P_2 = P_1+d$, falls in the second read. This requires:\n$G \\le P_1 \\le G+L-1$\n$G+I-L \\le P_1+d \\le G+I-1$\nSubstituting the given values, $L=150$, $I=350$, $d=200$:\n$G+350-150 \\le P_1+200 \\le G+350-1 \\Rightarrow G+200 \\le P_1+200 \\le G+349 \\Rightarrow G \\le P_1 \\le G+149$.\nThis condition is identical to the first one, $G \\le P_1 \\le G+L-1$. This means that any fragment where $P_1$ is captured by the first read will have $P_2$ captured by the second read. For example, if a fragment starts at $P_1-100$, the first read covers $[P_1-100, P_1+49]$ and contains $v_1$. The second read covers $[(P_1-100)+200, (P_1-100)+349] = [P_1+100, P_1+249]$ and contains $v_2$ (at $P_1+200$). Because the two reads in a pair originate from the same DNA molecule, observing the alleles at both positions across the pair determines their phase on that molecule. The description of finding molecules where \"both $v_1$ and $v_2$ co-occur\" is a valid potential outcome (establishing an in cis phase). The method itself is sound and robust given the library parameters. The high depth ($D=80\\times$) ensures that multiple such informative read-pairs would be sampled, making the result decisive.\n**Verdict: Correct.**\n\nC. This option describes a method based on analyzing messenger RNA (mRNA) transcripts. The variants are in exon $X$ and exon $X+1$. Reverse Transcription Polymerase Chain Reaction (RT-PCR) can be used to amplify the region of the mRNA (as cDNA) spanning both exons. Subsequently, cloning the PCR product into vectors and sequencing individual clones (e.g., via Sanger sequencing) allows for the reconstruction of individual transcript haplotypes. If the variants are in trans, the cell contains two types of mutant alleles: one producing transcripts with $v_1$ (and wild-type sequence at exon $X+1$) and another allele producing transcripts affected by the $v_2$ splice site variant (e.g., skipping exon $X+1$, but wild-type at the $v_1$ position). Therefore, sequencing individual cDNA clones would reveal two distinct populations of mutant transcripts: one with $v_1$ only, and one showing the consequence of $v_2$ only. Finding no clones that carry both mutations would be decisive evidence for an in trans configuration. This is a classic, robust molecular biology technique for phasing variants that are expressed in the chosen tissue (fibroblasts are appropriate as they express type VII collagen).\n**Verdict: Correct.**\n\nD. This option proposes statistical phasing. This computational method infers phase by comparing the proband's genotype to a reference panel of known population haplotypes. It relies on the principle of linkage disequilibrium. The problem explicitly states that \"$v_1$ and $v_2$ are rare and not present in population haplotype panels.\" If the variants are not in the reference database, or are too rare to have established co-occurrence statistics, the algorithm has no information upon which to base an inference. Therefore, statistical phasing is not a valid or robust method in this specific scenario. The conclusion that it is \"sufficient\" is incorrect.\n**Verdict: Incorrect.**\n\nE. This option suggests using Immunofluorescence (IF) microscopy to examine protein expression. IF can visualize the amount and localization of type VII collagen at the dermal-epidermal junction. \"Severely reduced\" protein levels are the expected phenotype for a patient with two loss-of-function alleles, as would be the case if $v_1$ and $v_2$ are in trans. If they were in cis, one functional allele would remain, likely producing a substantial amount (e.g., $\\approx 50\\%$) of collagen, leading to a milder or absent phenotype. While the protein-level observation is consistent with and supports the in trans hypothesis, it is not a direct or decisive method to establish the genetic phase. Protein expression can be influenced by many factors, and IF is often semi-quantitative at best. It infers genotype from phenotype, which is the reverse of the required logical direction and is not considered a primary method for phasing. It provides correlative evidence, not a definitive determination of the disposition of variants on the chromosome.\n**Verdict: Incorrect.**\n\nF. This option describes using Oxford Nanopore Technologies (ONT) long-read sequencing. This technology generates reads that are thousands to tens of thousands of base pairs long. The variants are separated by only $d=200$ bp. It is trivial to design a long-range PCR experiment to amplify a multi-kilobase region containing both variants, and then sequence these amplicons with ONT. Each resulting long read originates from a single DNA molecule and will easily span both variant sites. By inspecting individual reads, one can directly observe which alleles are present on the same molecule. The finding that some reads carry the haplotype ($v_1$, WT) and other reads carry the haplotype (WT, $v_2$), with no reads carrying ($v_1$, $v_2$), provides direct, single-molecule, and thus decisive, evidence for an in trans configuration. This is a very powerful and robust method for phasing.\n**Verdict: Correct.**", "answer": "$$\\boxed{ABCF}$$", "id": "4442428"}]}